Please login to the form below

Not currently logged in
Email:
Password:

dolutegravir

This page shows the latest dolutegravir news and features for those working in and with pharma, biotech and healthcare.

GSK considers more divestments to help R&D push

GSK considers more divestments to help R&D push

HIV sales through the ViiV Healthcare joint venture showed signs of weakness, as Tivicay (dolutegravir) continued to decline in the face of strong competition from Gilead Sciences, particularly its fast-growing ... There was an acceleration in sales of

Latest news

  • ViiV builds case for switching to its two-drug HIV combinations ViiV builds case for switching to its two-drug HIV combinations

    48-week data from the phase 3 TANGO study indicates that Dovato (dolutegravir/lamivudine) was just as effective as triple therapies that included Gilead’s tenofovir alafenamide fumarate (TAF) at suppressing ... diagnosed patients and Juluca

  • ViiV bags EU okay for new two-drug HIV therapy ViiV bags EU okay for new two-drug HIV therapy

    Dovato – a fixed-dose combination of ViiV’s blockbuster integrase inhibitor Tivicay (dolutegravir) and the nucleoside reverse transcriptase inhibitor lamivudine – is integral to the company’s attempt to muscle out ... Dovato is the second

  • Shingrix lifts GSK in Q1, but two more vaccines are culled Shingrix lifts GSK in Q1, but two more vaccines are culled

    The bulk of GSK’s HIV sales come from its dolutegravir-based combination products Tivicay and Triumeq, but greater competition in the market from arch-rival Gilead Sciences with new products ... GSK is looking to a series of new two-drug HIV drugs to

  • CHMP nod for Alexion, GSK drugs, revocation for Lartruvo CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

    Meanwhile, Dovato (dolutegravir/lamivudine) developed by GSK-led joint venture ViiV, is the first ever once-a-day two-drug STR for treatment-naïve patients.

  • Dovato approval key for Glaxo in HIV treatment Dovato approval key for Glaxo in HIV treatment

    Dovato (dolutegravir/lamivudine) is marketed by GSK-led joint venture ViiV, and is the first ever once-a-day two-drug STR for treating treatment-naïve patients. ... those who would otherwise be precluded from receiving [ViiV's] Triumeq

More from news
Approximately 6 fully matching, plus 50 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Developing your patient-centric strategy

    The 2013 PatientView survey likely scored ViiV well on the product front too, as 2013 saw the company’s HIV therapy Tivicay (dolutegravir) approved in the US and recommended for European

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...